July 16th, 2014
Findings from HPS2-THRIVE raise uncomfortable questions for physicians.
September 19th, 2012
A print ad for Niaspan focuses only on how it raises HDL-cholesterol levels, with no mention of the lack of benefit in improving outcomes.
May 26th, 2011
The AIM-HIGH (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglycerides: Impact on Global Health) trial of niacin has been stopped early by the NHLBI. The trial was designed to test the addition of high-dose, extended-release niacin to statins in people at risk for CV events who had well-controlled LDL but low HDL and elevated […]